beta

ANTH

Anthera Pharmaceuticals Inc.

Anth

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

05-15-2018 03-05-2018 11-06-2017 08-09-2017 05-10-2017
Actual EPS -0.42 -0.73 -0.58 -0.86 -2.03
Consensus EPS -0.6 -0.71 -0.9 -1.08 -1.39
Estimated EPS -0.6 -0.71 -0.9 -1.08 -1.39
Number of Estimates 2 4 3 3 2
EPS Surprise $0.18 -$0.02 $0.32 $0.22 -$0.64

Stats

Summary

Anthera Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapeutics to treat serious diseases.

Market Cap: 40.4 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.anthera.com

Shares Outstanding: 21.5 Million

Float: 20.6 Million

Dividend: 0.0 (0.0%)

Beta: 2.761304

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 1.11 Million

Ethical Flags

Animal testing

Longest drawdown: 749 trading days

From: 2015-07-27 To: 2018-06-28

Lowest Point:

Anthera Pharma to be delisted tomorrow; shares down 33.5%

via: SeekingAlpha at 2018-06-27 09:10:13:000

The company has withdrawn its request for a hearing to appeal its delisting determination at Nasdaq. Trading will be suspended at the open tomorrow. More news on: Anthera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Anthera Pharma to be delisted tomorrow; shares down 33.5%

via: SeekingAlpha at 2018-06-27 09:10:13:000

The company has withdrawn its request for a hearing to appeal its delisting determination at Nasdaq. Trading will be suspended at the open tomorrow. More news on: Anthera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Anthera Pharma to be delisted tomorrow; shares down 33.5%

via: SeekingAlpha at 2018-06-27 09:10:13:000

The company has withdrawn its request for a hearing to appeal its delisting determination at Nasdaq. Trading will be suspended at the open tomorrow. More news on: Anthera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space

via: SeekingAlpha at 2018-04-09 13:39:22:000

I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...

Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space

via: SeekingAlpha at 2018-04-09 13:39:22:000

I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...

Anthera Fails Phase 3 Study, Time To Avoid

via: SeekingAlpha at 2018-03-15 13:54:10:000

Recently, Anthera Pharmaceuticals ( ANTH ) reported results from its Phase 3 trial treating exocrine pancreatic insufficiency ((EPI)) due to cystic fibrosis. It noted that the Phase 3 study failed to meet the primary endpoint . This sent shares of Anthera trading lower for… read more...

Anthera Fails Phase 3 Study, Time To Avoid

via: SeekingAlpha at 2018-03-15 13:54:10:000

Recently, Anthera Pharmaceuticals ( ANTH ) reported results from its Phase 3 trial treating exocrine pancreatic insufficiency ((EPI)) due to cystic fibrosis. It noted that the Phase 3 study failed to meet the primary endpoint . This sent shares of Anthera trading lower for… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: March 13, 2018

via: SeekingAlpha at 2018-03-14 14:21:51:000

The inflation data released today was underwhelming (bullish for stocks). Today was a small pullback day for U.S. equities after the recent rally from February lows but new highs are likely. Anthera Pharmaceuticals ( ANTH ) is trading at a market cap of just $11.3 million after the failur… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: March 13, 2018

via: SeekingAlpha at 2018-03-14 14:21:51:000

The inflation data released today was underwhelming (bullish for stocks). Today was a small pullback day for U.S. equities after the recent rally from February lows but new highs are likely. Anthera Pharmaceuticals ( ANTH ) is trading at a market cap of just $11.3 million after the failur… read more...

3 Things In Biotech, March 13, 2018: Uncertainty Abounds!

via: SeekingAlpha at 2018-03-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners' Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biote… read more...

3 Things In Biotech, March 13, 2018: Uncertainty Abounds!

via: SeekingAlpha at 2018-03-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners' Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biote… read more...

Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow

via: SeekingAlpha at 2018-03-13 13:17:24:000

The following slide deck was published by Anthera Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow

via: SeekingAlpha at 2018-03-13 13:17:24:000

The following slide deck was published by Anthera Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Your Daily Pharma Scoop: Coherus Biosciences Surges, Savara's Aironite Flops, Biogen's SPINRAZA

via: SeekingAlpha at 2018-03-13 07:30:00:000

Analysis of top Seeking Alpha coverage: Coherus Biosciences Today we will discuss Coherus Biosciences (CHRS), which surged last Friday after the company announced that it is set to resubmit its application for Neulasta biosimilar. The company also noted that it expects an approval for the… read more...

Your Daily Pharma Scoop: Coherus Biosciences Surges, Savara's Aironite Flops, Biogen's SPINRAZA

via: SeekingAlpha at 2018-03-13 07:30:00:000

Analysis of top Seeking Alpha coverage: Coherus Biosciences Today we will discuss Coherus Biosciences (CHRS), which surged last Friday after the company announced that it is set to resubmit its application for Neulasta biosimilar. The company also noted that it expects an approval for the… read more...

Midday Gainers / Losers (3/12/2018)

via: SeekingAlpha at 2018-03-12 12:45:10:000

Gainers: BXC +83% . RKDA +51% . MARA +31% . OCLR +27% . NETE +23% . UCBA +23% . CPAH +18% . IMMP +17% . JNP +17% . More news on: BlueLinx Holdings, Inc., Arcadia Biosciences, Marathon Patent Group, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (3/12/2018)

via: SeekingAlpha at 2018-03-12 12:45:10:000

Gainers: BXC +83% . RKDA +51% . MARA +31% . OCLR +27% . NETE +23% . UCBA +23% . CPAH +18% . IMMP +17% . JNP +17% . More news on: BlueLinx Holdings, Inc., Arcadia Biosciences, Marathon Patent Group, Inc., Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (3/12/2018)

via: SeekingAlpha at 2018-03-12 09:11:08:000

ANTH -84% on terminating development of Sollpura after failed late-stage study. More news on: Anthera Pharmaceuticals, Inc., Orexigen Therapeutics, Inc., Savara Inc., Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (3/12/2018)

via: SeekingAlpha at 2018-03-12 09:11:08:000

ANTH -84% on terminating development of Sollpura after failed late-stage study. More news on: Anthera Pharmaceuticals, Inc., Orexigen Therapeutics, Inc., Savara Inc., Stocks on the move, , Read more … read more...

Anthera to terminate development of Sollpura after failed late-stage study

via: SeekingAlpha at 2018-03-12 08:21:23:000

Nano cap Anthera Pharmaceuticals (NASDAQ: ANTH ) is set for an ugly day after announcing that lead candidate Sollpura failed to demonstrate non-inferiority to Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' PANCREAZE (pancrelipase) in a Phase 3 study. More news on: Anthe… read more...

Anthera to terminate development of Sollpura after failed late-stage study

via: SeekingAlpha at 2018-03-12 08:21:23:000

Nano cap Anthera Pharmaceuticals (NASDAQ: ANTH ) is set for an ugly day after announcing that lead candidate Sollpura failed to demonstrate non-inferiority to Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' PANCREAZE (pancrelipase) in a Phase 3 study. More news on: Anthe… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-03-09 08:12:01:000

Endocyte (NASDAQ: ECYT ) initiated with Outperform rating and $20 (150% upside) price target at Wells Fargo. Shares up 4% premarket on modest volume. More news on: Endocyte, Inc., Corcept Therapeutics Incorporated, Masimo Corporation, Healthcare stocks news, Stocks on the move,… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-03-09 08:12:01:000

Endocyte (NASDAQ: ECYT ) initiated with Outperform rating and $20 (150% upside) price target at Wells Fargo. Shares up 4% premarket on modest volume. More news on: Endocyte, Inc., Corcept Therapeutics Incorporated, Masimo Corporation, Healthcare stocks news, Stocks on the move,… read more...

Stocks To Watch: Digging For Gems In The Shakeout

via: SeekingAlpha at 2018-02-10 08:37:29:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Are you not entertained? The broad-based selling in equities in the U.S. and across… read more...

Stocks To Watch: Digging For Gems In The Shakeout

via: SeekingAlpha at 2018-02-10 08:37:29:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Are you not entertained? The broad-based selling in equities in the U.S. and across… read more...

Stocks To Watch: Digging For Gems In The Shakeout

via: SeekingAlpha at 2018-02-10 08:37:29:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Are you not entertained? The broad-based selling in equities in the U.S. and across… read more...

Stocks To Watch: Digging For Gems In The Shakeout

via: SeekingAlpha at 2018-02-10 08:37:29:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Are you not entertained? The broad-based selling in equities in the U.S. and across… read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List

via: SeekingAlpha at 2018-02-06 11:42:23:000

Welcome to the 76th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Midday Gainers / Losers (1/24/2018)

via: SeekingAlpha at 2018-01-24 12:46:54:000

Gainers: OPGN +58% . ACHV +51% . OHGI +29% . HTM +27% . SRT +20% . CERS +18% . RFIL +17% . CARA +17% . ANTH +16% . GWW +16% . More news on: OpGen, Achieve Life Sciences, Inc., One Horizon Group, Inc., Stocks on the move, Read more … read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

ROTY Edition 1 Volume 72: Biotech Shines In January As We Manage Risk Appropriately

via: SeekingAlpha at 2018-01-23 13:23:39:000

Welcome to the 72nd entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Your Daily Pharma Scoop: Omeros' OMS721, Celgene To Acquire Juno, BioCryst And Idera To Merge

via: SeekingAlpha at 2018-01-23 08:00:00:000

Analysis of Top Seeking Alpha Coverage: Omeros Corporation Today we will discuss Omeros' ( OMER ) OMS721, which achieved yet another milestone. Omeros announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) gave a positive opinion on the applic… read more...

Anthera on go to report results from late-stage study of Sollpura in EPI this quarter; shares ahead 3%

via: SeekingAlpha at 2018-01-22 10:18:45:000

Anthera Pharmaceuticals ( ANTH +3.1% ) is up on 40% higher volume in response to its announcement that the second pre-planned futility analysis has been completed on the Phase 3 RESULT study assessing Sollpura for the treatment of exocrine pancreatic insufficiency (EPI). More news on: … read more...

Premarket Gainers as of 9:05 am (1/22/2018)

via: SeekingAlpha at 2018-01-22 09:24:28:000

BIVV +63% on being acquired vy Sanofi (NYSE: SNY ). More news on: Bioverativ Inc., Sanofi, Validus Holdings, Ltd., Stocks on the move, Read more … read more...

ROTY Edition 1 Volume 70: A Solid Start To January And Thoughts On Taking Profits

via: SeekingAlpha at 2018-01-16 12:34:36:000

Welcome to the 70th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Omeros: Competition In IgAN, But OMS721 Has The Lead

via: SeekingAlpha at 2018-01-11 05:42:31:000

Omeros Corporations ( OMER ) lead drug candidate is OMS721, which is going through trials in IgA Nephropathy. We have covered the stock extensively, and readers know we are bullish OMER. However, we would be remiss in our due diligence if we did not discuss some of the main competition… read more...

ROTY Edition 1 Volume 69: BTD For Global Blood Therapeutics And Other Updates

via: SeekingAlpha at 2018-01-10 09:33:49:000

Welcome to the 69th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 61: ASH Updates And Trades

via: SeekingAlpha at 2017-12-12 08:34:24:000

Welcome to the 61st entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2017-05-01 8.0 1.0 8.0
2013-07-15 8.0 1.0 8.0
Data provided for free by IEX